Dr. Nicholas Lydon has extensive experience in drug discovery and development and is one of the three recipients of the 2009 Lasker Award for the discovery of Imatinib and its applications in the treatment of Chronic Myeloid Leukemia. His work broke new ground in cancer therapy and radically changed the prognosis of CML patients.
Dr. Lydon is a co-founder and Director of AnaptysBio (San Diego, USA) and of BluePrint Medicines (Cambridge, USA). He previously served as Vice President at Amgen and was also the CEO and founder of Kinetix Pharmaceuticals, a biotechnology company focused on the discovery and development of selective protein kinase inhibitors.
Dr. Lydon also worked at CIBA-GEIGY (now Novartis), in Basel, Switzerland, where he was responsible for the tyrosine protein kinase inhibitor program, including the discovery and preclinical development of Imatinib (Gleevec®). He has been awarded the 2009 Lasker Award and the 2012 Japan Prize for his groundbreaking work on this molecule.
This speaker is brought to you with the support of ASPIC.